Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AMTI | Common Stock | Award | $0 | +886K | +1473.02% | $0.00 | 946K | Sep 28, 2023 | Direct | F1 |
transaction | AMTI | Common Stock | Sale | -$30.7K | -194K | -20.5% | $0.16 | 752K | Sep 29, 2023 | Direct | F2, F3 |
Id | Content |
---|---|
F1 | The reported shares are represented by restricted stock units, or RSUs. 443,055 RSUs vested upon signing of the Agreement and Plan of Merger dated as of September 21, 2023, among Cyclo Therapeutics, Inc., a Nevada corporation, Cameo Merger Sub, Inc., a Delaware corporation and the Issuer (the "Merger Agreement"). The remaining 443,056 RSUs vest as to 50% on the date that is five trading days following the filing of the proxy/prospectus relating to stockholder approval of the merger contemplated by the Merger Agreement (the "Form S-4") and 50% on the date the Form S-4 is declared effective by the SEC. |
F2 | Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of RSUs. This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. |
F3 | A portion of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |